Advertisement

Clinical Approach

  • Sergio Cosciani Cunico
  • Alessandra Moroni
  • Giuseppe Mirabella
  • Claudio Simeone
  • Lucio Olivetti

Abstract

Tumors of the male urogenital system are frequent (with an incidence in the United States of 25%). They usually have a long latency period and a high percentage of posttherapy survival. Patients affected by malignant urogenital lesions therefore require a long period of monitoring to identify recurrence of disease requiring adjuvant or salvage treatment as early as possible. The task of the urologist is to identify a strategy which on the one hand guarantees patient safety and on the other maintains costs within acceptable levels. This is prompted by the fact that apart from clinical and laboratory findings, patient follow-up principally consists of radiologic examinations.

Keywords

Prostate Specific Antige Testicular Cancer Male Reproductive System Positron Emission Tomo Plain Chest Film 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bradford T, Montie J, Hafez KS (2006) The role of imaging in the surveillance of urologic malignancies. Urol Clin N Am 33:377–396CrossRefGoogle Scholar
  2. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin. 55:10–30CrossRefPubMedGoogle Scholar
  3. Janzen NK, Kim HL, Figlin RA et al (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30:843–852CrossRefGoogle Scholar
  4. Rabinovitch RA, Zelefsky MJ, Gaynor JJ et al (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12:206–212PubMedGoogle Scholar
  5. Stephenson AJ, Chetner MP, Rourke K et al (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58–62CrossRefPubMedGoogle Scholar
  6. Deligne E, Colombel M, Badet L et al (2002) Conservative management of upper urinary tract tumors. Eur Urol 42:43–48CrossRefPubMedGoogle Scholar
  7. Jabbour ME, Smith AD (2000) Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin N Am 27:739–750CrossRefGoogle Scholar
  8. Bradford TJ, Montie JE, Hafez KS (2006) The role of imaging in the surveillance of the urologic malignancies. Urol Clin N Am 33:377–396CrossRefGoogle Scholar
  9. Herr HW, Bochner BH, Dalbagni G et al (2002) Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167:1295–1298CrossRefPubMedGoogle Scholar
  10. Kuroda M, Meguro M, Maeda O et al (2002) Stage-specific follow-up strategy after cystectomy for carcinoma of the bladder. Int J Urol 9:126–133Google Scholar
  11. Oosterlink W, Lobel B, Jakse G et al (2002) Guidelines on bladder cancer. Eur Urol 41:105–112CrossRefGoogle Scholar
  12. Cher ML, Bianco FJ Jr, Lam JS et al (1998) Limited role of radionuclide bone scintigraphy in patients with PSA elevations after radical prostatectomy. J Urol 160:1387–1391CrossRefPubMedGoogle Scholar
  13. Koppie TM, Grossfeld GD, Nuddell DM et al (2001) Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166:111–115CrossRefPubMedGoogle Scholar
  14. Messing EM, Thompson I Jr (2003) Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin N Am 30:687–702CrossRefGoogle Scholar
  15. Nelson JB, Lepor H (2003) Radical prostatectomy. Urol Clin N Am 30:703–723CrossRefGoogle Scholar
  16. Shvarts O, Han KR (2002) PET in urologic oncology. Cancer Control 9:335–342PubMedGoogle Scholar
  17. Hendry WF, Norman AR, Dearnaley DP et al (2002) Metastatic nonseminomatous germ cell tumors of testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668–1676CrossRefPubMedGoogle Scholar
  18. Laguna MP, Pizzocaro G, Klepp O et al (2001) EAU guidelines on testicular cancer. Eur Urol 40:102–110CrossRefPubMedGoogle Scholar
  19. Livesey JE, Taylor B, Mobarek N et al (2001) Patterns of relapse following radiotherapy for stage I seminoma of testis: implications for follow-up. Clin Oncol 13:296Google Scholar
  20. Purdue MP, Devesa SS, Sigurdson AJ et al (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115:822–827CrossRefPubMedGoogle Scholar
  21. Spermon JR, Roeleveld TA, van der Poel HG et al (2002) Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 59:923–929CrossRefPubMedGoogle Scholar
  22. Spermon JR, Witjes JA, Kiemeney LA (2004) Efficacy of routine follow-up after first-line treatment for testicular cancer. World J Urol 22:235–243CrossRefPubMedGoogle Scholar
  23. Solsona E, Algaba F, Horenblas S et al (2004) EAU guidelines on penile cancer. Eur Urol 46:1–8CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sergio Cosciani Cunico
    • 1
  • Alessandra Moroni
    • 1
  • Giuseppe Mirabella
    • 1
  • Claudio Simeone
    • 1
  • Lucio Olivetti
    • 2
  1. 1.Department of UrologyUniversity of Brescia A. O. Spedali CiviliBresciaItaly
  2. 2.Department of Diagnostic ImagingIstituti Ospitalieri di CremonaCremonaItaly

Personalised recommendations